ImmunoMet Therapeutics
PrivateLast Round
Series C
Oct 19, 2022
Total Funding Raised
$39M
Company Overview
ImmunoMet Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for cancer and fibrosis by targeting cellular metabolism. Founded in 2015 as a spin-off from HanAll Biopharma, the company's lead candidate is lixumistat (IM156), an oral inhibitor of protein complex 1 (PC1) that targets Oxidative Phosphorylation (OxPhos). This mechanism aims to decrease the growth and proliferation of cancer cells and fibrosis. The company is actively conducting clinical trials for various indications, including pancreatic cancer and solid tumors. ImmunoMet is privately held and venture capital-backed, having completed multiple funding rounds to advance its pipeline.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ImmunoMet Therapeutics Comps
Public and private peers based on sector, stage, and business model.
ImmunoMet Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Oct 19, 2022 | ||||
| Series B Extension | Dec 31, 2021 | ||||
| Series B Extension | Feb 5, 2020 | ||||
| Convertible Debt | May 16, 2018 | ||||
| Series B | Mar 7, 2017 | ||||
Series A | Mar 8, 2016 |
Key People
Founding team and executive leadership
ImmunoMet Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| InterVest | Series B |
| SL Investment | Series B |
| NHN Investment | Series B |
| Mirae Asset Venture Investments | Series B, Series A |
ImmunoMet Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about ImmunoMet Therapeutics's valuation, stock price, and market status.
